BIO-Europe Spring® 2014: Who will finance early stage drug discovery?

March 27, 2014
Common wisdom holds that it is getting harder and harder to find funding for drug discovery—yet financing data show that private rounds for companies whose lead programs are in preclinical development and earlier have been steadily rising since the meltdown. On top of that, big pharma is increasingly partnering directly with academics on discovery research, as well as participating in regional incubators that support early stage startups. For more information on BIO-Europe Spring, visit our webpage: http://www.ebdgroup.com/bes/index.php Please view the rest of the video at http://www.partnering360.com/insight/showroom/id/484
Previous Video
BIO-Europe Spring® 2014: Pharma steps up early on relevance data
BIO-Europe Spring® 2014: Pharma steps up early on relevance data

For valuations on biotech/pharma deals, one principle has been inviolate: later stage programs, especially ...

Next Video
How to use partnering360 to reach collaborators and make deals in the global life science industry
How to use partnering360 to reach collaborators and make deals in the global life science industry

Join the gateway to the life science community using EBD Group's life science partnering platform partnerin...